.jpg)
Competitive Intelligence & Portfolio Strategy
Licensed platforms, internal pipeline records, and trial registries each track the same drug, target, or company differently. That leaves blind spots just when a stop-or-go or in-licensing decision needs the full picture.
DISQOVER connects it all in one searchable knowledge layer, so teams track competitors by drug, target, or indication, not by vendor export.
The data you already have
Competitive intelligence data integration means connecting licensed pipeline intelligence, internal portfolio records, and public trial and patent data into one place a team can query, without replacing the vendor platforms already in use.
You do not need new data to get value from DISQOVER: competitive intelligence and portfolio strategy teams already work with a recognizable set of public, proprietary, and licensed sources, and DISQOVER connects them.
How it works
DISQOVER resolves two problems at once: vendors naming and structuring the same drug, target, or company differently, and relationships between programs, indications, trials, and patents that span sources. On top of that, it shows which source contributed what.
Drug, target, and company names that differ across licensed platforms resolve to a single concept automatically, including near-matches where vendors use slightly different spellings or identifiers. A search does not need to know which platform used which label.
Drugs, targets, indications, clinical trials, and patents are linked in a knowledge graph, so a team can move from a target to its associated drugs, trials, and patent activity in one traversal, instead of cross-referencing vendor platforms by hand.
Every result links back to its source, version, and context. Because licensed vendors often disagree, teams can see which source contributed which fact, so discrepancies surface instead of one answer being picked silently.
Competitor reports
A single drug or target rarely tells the full competitive story. Understanding a competitor means pulling their pipeline, trial activity, and patent position together at the company level, not just the compound level.
DISQOVER generates these reports automatically from licensed sources such as Cortellis, Pharmaprojects, and Trialtrove, combined with internal BD records and public trial and patent data. One report rolls up a named competitor's active pipeline, phase distribution, and patent activity, instead of three vendor exports stitched together by hand.
Outcomes
The risk sits in what no single source shows.
Stop-or-go, in-licensing, and due diligence decisions need the full competitive landscape. That landscape is spread across licensed platforms, internal pipeline records, patents, and trial registries. DISQOVER reconciles them into one view your team can query.
Assessing an in-licensing candidate usually means exporting from several licensed platforms and mapping the results by hand. With those sources already reconciled, teams spend their effort on the analysis instead. The return is due diligence time spent on the decision, not on preparing the data behind it.
Licensed platforms and internal BD records are aligned to one shared entity model, so there is nothing left to map by hand.
Querying licensed platforms one at a time hides where they disagree. Because every fact is traced to its source, gaps and conflicts between vendors become visible before a decision rests on them. The return is fewer decisions built on an incomplete landscape, and evidence to bring to vendor negotiations.
Source-level provenance shows where vendors agree, where they conflict, and where each one fills a gap the others leave.
A competitor's pipeline, trials, and patent position roll up into a single report that is rerun whenever the sources update, and every figure in it traces back to the trial or patent behind it. The return is competitor profiles that stay current without being rebuilt by hand.
Phase distribution across a competitor's whole pipeline breaks down to the individual programs behind it.
Every data vendor you subscribe to tells part of the story. DISQOVER puts the parts together.
See it in action
In this walkthrough, Claude is connected to DISQOVER through its MCP interface and asked to map the competitive landscape around imatinib.
Customer story
This customer built an internal knowledge graph program, with DISQOVER as the front-end knowledge browser, to unify competitive intelligence from three licensed providers: Cortellis, Pharmaprojects, and Trialtrove. Rather than only deduplicating drug names, the team aligned each source down to development status, company details, patents, and target association, mapping every entity to a shared canonical type.
Through DISQOVER MCP, an AI agent can take a question like "map the competitive landscape around drug X," resolve the drug to its precise instance in the graph, and assemble a report grounded in harmonized public, internal, and third-party data, with every finding versioned and traceable to its source.
DISQOVER ships with industry-standard ontologies and domain-specific entity models out of the box, so competitive intelligence concepts are understood from day one. For competitive intelligence and portfolio strategy, that includes:
Beyond matching drug names, DISQOVER aligns licensed intelligence sources at the level of development status, company details, patents, and target association, with fuzzy matching for drug and company name variants.
Where vendors disagree or fill different gaps, DISQOVER shows it, rather than silently merging conflicting records.
DISQOVER tracks which sources contributed to every data point, so visibility can be restricted by user group without separate access-management tooling, consistent across the UI and the API.
This matters when licensed vendor data, with its own access and usage terms, sits alongside internal pipeline data in the same knowledge layer.
FAQ
Competitive intelligence data integration means connecting licensed pipeline intelligence platforms, internal portfolio records, and public trial and patent data into one searchable layer, so a team can see the full competitive picture for a drug or target without manually cross-referencing multiple vendor exports.
DISQOVER aligns each vendor's data to a shared canonical entity model, matching not just drug names but development status, company details, patents, and target association, including fuzzy matching for spelling variants. Where vendors disagree, DISQOVER surfaces the discrepancy rather than silently choosing one source.
Yes. DISQOVER's knowledge graph links drugs, targets, indications, clinical trials, and patents, so a team can traverse from a target or indication to every associated competitor program in one view, rather than searching each vendor platform separately.
Through DISQOVER's MCP interface, a question like "map the competitive landscape around this drug" returns a report grounded in harmonized public, internal, and third-party data, with every finding versioned and traceable back to its source.
No. DISQOVER connects and harmonizes data from licensed platforms like Cortellis, Pharmaprojects, and Trialtrove alongside internal pipeline data; it does not replace the underlying subscriptions. The value is in reconciling what those sources say into one queryable view.
Talk to us about reconciling your licensed intelligence platforms, internal pipeline records, and public trial and patent data into one view your team can query.
ONTOFORCE enables life science companies to unlock hidden insights from data.
With DISQOVER, built on knowledge graph technology, we support life sciences and pharmaceutical companies with innovative data management and visualization.
